Intervention Review

You have free access to this content

Chinese herbal medicine Huangqi type formulations for nephrotic syndrome

  1. Mei Feng1,2,
  2. Wei Yuan3,
  3. Renzhong Zhang1,
  4. Ping Fu1,
  5. Taixiang Wu4,*

Editorial Group: Cochrane Renal Group

Published Online: 5 JUN 2013

Assessed as up-to-date: 30 APR 2011

DOI: 10.1002/14651858.CD006335.pub3


How to Cite

Feng M, Yuan W, Zhang R, Fu P, Wu T. Chinese herbal medicine Huangqi type formulations for nephrotic syndrome. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD006335. DOI: 10.1002/14651858.CD006335.pub3.

Author Information

  1. 1

    West China Hospital, Sichuan University, Department of Nephrology, Chengdu, Sichuan, China

  2. 2

    Sichuan Cancer Hospital, Radiation Oncology, Chengdu, China

  3. 3

    Tianjin First Center Hospital, Tianjin, China

  4. 4

    West China Hospital, Sichuan University, Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, Chengdu, Sichuan, China

*Taixiang Wu, Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. txwutx@hotmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 5 JUN 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 1 Complete remission.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 2 Partial remission.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 3 Urine albumin excretion.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 4 Plasma albumin.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 5 Triglycerides.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 6 Cholesterol.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 7 Time to oedema remission.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 8 No improvement at 3 months.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 9 Relapse.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 10 Complications.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Huangqi and Huangqi type formulations versus control drugs, Outcome 11 Adverse reactions.